Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma

NCT02812706 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02812706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02812706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Completed
Start date
September 5, 2016
Completion date
September 28, 2022
Enrollment
36 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma